{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:47:11Z","timestamp":1775846831348,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) with t(8;21) is a subset of core binding factor AML and is considered to be favorable risk disease in patients receiving intensive cytarabine based chemotherapy. However, relapse remains a significant clinical challenge. Mutations in\n                    <jats:italic>KIT<\/jats:italic>\n                    , which frequently co-occur in t(8;21) AML, have been associated with worse relapse free and overall survival. Avapritinib is a novel tyrosine kinase inhibitor targeting KIT mutations that is approved for systemic mastocytosis but doesn\u2019t currently have an established role in the treatment of AML. We present a case of a patient with extensively treated KIT D816H-mutated t(8;21) AML who experienced relapse after an allogeneic hematopoietic stem cell transplant and achieved a deep remission rapidly with avapritinib monotherapy. This case highlights the potential role of avapritinib as a targeted therapy for relapsed t(8;21) AML with KIT mutations, warranting further clinical investigation.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06388-w","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:43:24Z","timestamp":1750999404000},"page":"3889-3892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review"],"prefix":"10.1007","volume":"104","author":[{"given":"Ted M.","family":"Getz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Bakirhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Seropian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"6388_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/S41408-021-00503-6","volume":"11","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Kantarjian H (2021) Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 11:114. https:\/\/doi.org\/10.1038\/S41408-021-00503-6","journal-title":"Blood Cancer J"},{"key":"6388_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/BLOOD-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united Kingdom medical research Council trials. Blood 116:354\u2013365. https:\/\/doi.org\/10.1182\/BLOOD-2009-11-254441","journal-title":"Blood"},{"key":"6388_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/BLOODADVANCES.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Group for the JALS, Kawashima N et al (2020) Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv 4:66\u201375. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2019000709","journal-title":"Blood Adv"},{"key":"6388_CR4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1182\/BLOOD-2018-05-852822","volume":"133","author":"F Christen","year":"2019","unstructured":"Christen F, Hoyer K, Yoshida K et al (2019) Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood 133:1140\u20131151. https:\/\/doi.org\/10.1182\/BLOOD-2018-05-852822","journal-title":"Blood"},{"key":"6388_CR5","doi-asserted-by":"publisher","unstructured":"Katagiri S, Chi S, Minami Y et al (2022) Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/IJMS23094694\/S1","DOI":"10.3390\/IJMS23094694\/S1"},{"key":"6388_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41375-018-0129-6","volume":"32","author":"P Paschka","year":"2018","unstructured":"Paschka P, Schlenk RF, Weber D et al (2018) Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia\u2014results of the AMLSG 11\u2013\u200908 trial. Leuk 2018 32:7. https:\/\/doi.org\/10.1038\/s41375-018-0129-6","journal-title":"Leuk 2018"},{"key":"6388_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/BLOODADVANCES.2019000492","volume":"4","author":"G Marcucci","year":"2020","unstructured":"Marcucci G, Geyer S, Laumann K et al (2020) Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv 4:696\u2013705. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2019000492","journal-title":"Blood Adv"},{"key":"6388_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI et al (2021) Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 2021 27:12. https:\/\/doi.org\/10.1038\/s41591-021-01538-9","journal-title":"Nat Med 2021"},{"issue":"12","key":"6388_CR9","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH et al (2021) Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med 2021 27(12):2192\u20132199. https:\/\/doi.org\/10.1038\/s41591-021-01539-8","journal-title":"Nat Med 2021"},{"key":"6388_CR10","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/J.CLML.2021.11.015","volume":"22","author":"NF Shafik","year":"2022","unstructured":"Shafik NF, Ibraheem D, Selim MM et al (2022) The prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 22:e363\u2013e375. https:\/\/doi.org\/10.1016\/J.CLML.2021.11.015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6388_CR11","doi-asserted-by":"publisher","first-page":"100371","DOI":"10.1016\/J.LRR.2023.100371","volume":"19","author":"L Sandow","year":"2023","unstructured":"Sandow L, Heinrich M (2023) Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia. Leuk Res Rep 19:100371. https:\/\/doi.org\/10.1016\/J.LRR.2023.100371","journal-title":"Leuk Res Rep"},{"key":"6388_CR12","doi-asserted-by":"publisher","unstructured":"Yin J, Zhu F, Zhang ZB et al (2022) Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation. https:\/\/doi.org\/10.1007\/S00277-022-04897-6. Ann Hematol 101:","DOI":"10.1007\/S00277-022-04897-6"},{"key":"6388_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/S41409-023-01973-X","volume":"58","author":"J Kong","year":"2023","unstructured":"Kong J, Zheng FM, Wang ZD et al (2023) Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 58:777\u2013783. https:\/\/doi.org\/10.1038\/S41409-023-01973-X","journal-title":"Bone Marrow Transpl"},{"key":"6388_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/10428194.2022.2064994","volume":"63","author":"S Xue","year":"2022","unstructured":"Xue S, Huang W, Liu F et al (2022) Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT. Leuk Lymphoma 63:2247\u20132250. https:\/\/doi.org\/10.1080\/10428194.2022.2064994","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06388-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06388-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T16:02:45Z","timestamp":1754668965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06388-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6388"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06388-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5932205\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for conducting this study. RMS had a consultancy with Bristol Myers Squibb, Curio Science, Gilead Sciences, Kura Oncology, Servier, and Rigel and served in Steering Committees for Servier. TMG, KB, and SS have no relevant financial or non-financial interests to disclose. The participant has consented to the submission of the case report to the journal. This case report adheres to the ethical standards set by Yale New Haven Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to publish"}},{"value":"RMS had a consultancy with Bristol Myers Squibb, Curio Science, Gilead Sciences, Kura Oncology, Servier, and Rigel and served in Steering Committees for Servier.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}